Ipsilateral silent period: A marker of callosal conduction abnormality in early relapsing-remitting multiple sclerosis?

被引:31
|
作者
Jung, Patrick
Beyerle, Astrid
Hurnpich, Marek
Neumann-Haefelin, Tobias
Lanfermann, Heinrich
Ziemann, Ulf
机构
[1] Univ Frankfurt, Dept Neurol, D-60528 Frankfurt, Germany
[2] Univ Frankfurt, Inst Neuroradiol, D-6000 Frankfurt, Germany
关键词
ipsilateral silent period; central motor conduction time; transcranial magnetic stimulation; corpus callosuni; relapsing-remitting multiple sclerosis;
D O I
10.1016/j.jns.2006.08.008
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Objective: The corpus callosum (CC) is commonly affected in multiple sclerosis (MS). The ipsilateral silent period (iSP) is a putative electrophysiological marker of callosal demyelination. The purpose of this study was to re-assess, under recently established optimised protocol conditions [Jung P., Ziemann U. Differences of the ipsilateral silent period in small hand muscles. Muscle Nerve in press.], its diagnostic sensitivity in MS, about which conflicting results were reported in previous studies. Methods: ISP measurements (onset, duration, and depth) were obtained in the abductor pollicis brevis (APB) muscle of either hand in 49 patients with early relapsing-remitting MS (RRMS) (mean EDSS, 1.3). Standard central motor conduction times to the APB (CMCTAPB) and tibial anterior muscles (CMCTTA), and magnetic resonance images (MRI) were also obtained. Results: ISP measurements showed a similar diagnostic sensitivity (28.6%) as CMCTAPB (24.5%), while diagnostic sensitivities of CMCTTA (69.4%) and MRI of the CC (78.6%) were much higher. Prolongation of iSP duration was the most sensitive single iSP measure. ISP prolongation occurred more frequently when CMCTAPB to the same hand was also prolonged (40.0% vs. 8.4%, p < 0.000 1). The correlation between iSP duration and CMCTAPB was significant (Pearson's r=0.24, p < 0.02), suggesting that iSP duration can be contaminated by demyclination of the contralateral corticospinal tract. ISP duration did not correlate with MRI abnon-nalities of the CC. Conclusions: ISP measures are neither a sensitive nor a specific marker of callosal conduction abnormality in early RRMS. (c) 2006 Elsevier B.V. All rights reserved.
引用
收藏
页码:133 / 139
页数:7
相关论文
共 50 条
  • [11] Glatiramer acetate for treatment of relapsing-remitting multiple sclerosis
    Johnson, Kenneth P.
    EXPERT REVIEW OF NEUROTHERAPEUTICS, 2012, 12 (04) : 371 - 384
  • [12] Advances in and Algorithms for the Treatment of Relapsing-Remitting Multiple Sclerosis
    Jens Ingwersen
    Orhan Aktas
    Hans-Peter Hartung
    Neurotherapeutics, 2016, 13 : 47 - 57
  • [13] Advances in and Algorithms for the Treatment of Relapsing-Remitting Multiple Sclerosis
    Ingwersen, Jens
    Aktas, Orhan
    Hartung, Hans-Peter
    NEUROTHERAPEUTICS, 2016, 13 (01) : 47 - 57
  • [14] Comorbidity in in patients with relapsing-remitting multiple sclerosis.
    Somilo, O., V
    Makarov, S. O.
    Kalbus, O., I
    MEDICNI PERSPEKTIVI, 2024, 29 (03): : 137 - 143
  • [15] Alemtuzumab induces severe orbitopathy in relapsing-remitting multiple sclerosis
    Gomez, Pablo Rodriguez de Vera
    Muros, Mariola Mendez
    Cuadro, Alberto Torres
    de Miera, Francisco Javier Toyos Saenz
    Ruiz, Rocio Lopez
    Vazquez, Raquel Guerrero
    Gonzalez, Juan Jesus Garcia
    Hermosilla, Antonio Manuel Garrido
    Hernandez, Tomas Martin
    JOURNAL OF NEUROLOGY, 2024, 271 (01) : 486 - 496
  • [16] Novel and imminently emerging treatments in relapsing-remitting multiple sclerosis
    Oh, Jiwon
    O'Connor, Paul W.
    CURRENT OPINION IN NEUROLOGY, 2015, 28 (03) : 230 - 236
  • [17] The clinical importance of neutralizing antibodies in relapsing-remitting multiple sclerosis
    Namaka, M
    Pollitt-Smith, M
    Gupta, A
    Klowak, M
    Vasconcelos, M
    Turcotte, D
    Gong, YW
    Melanson, M
    CURRENT MEDICAL RESEARCH AND OPINION, 2006, 22 (02) : 223 - 239
  • [18] Alemtuzumab: evidence for its potential in relapsing-remitting multiple sclerosis
    Brown, J. William L.
    Coles, Alasdair J.
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2013, 7 : 131 - 138
  • [19] Pausing and fluency in speech of patients with relapsing-remitting multiple sclerosis
    Bona, Judit
    CLINICAL LINGUISTICS & PHONETICS, 2024, 38 (04) : 332 - 344
  • [20] Beta-interferons in the therapy of relapsing-remitting multiple sclerosis
    Klimová, E
    Szilasiová, J
    CESKA A SLOVENSKA NEUROLOGIE A NEUROCHIRURGIE, 2003, 66 (05) : 343 - +